Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

- February 15th, 2019

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option … Continued

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share.

As quoted in the press release:

 All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.

The Company’s common stock is expected to commence trading on The Nasdaq Capital Market, on February 15, 2019 under the ticker symbol “HOTH”.  The offering is expected to close on February 20, 2019, subject to the satisfaction of customary closing conditions.

Laidlaw & Company (UK) Ltd. is acting as the sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering.

The offering is being made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 521 Fifth Avenue, New York, NY 10175, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *